Can-Fite BioPharma (NYSE:CANF – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Tuesday.
Separately, EF Hutton Acquisition Co. I upgraded shares of Can-Fite BioPharma to a “strong-buy” rating in a research note on Wednesday, July 17th.
Get Our Latest Stock Analysis on Can-Fite BioPharma
Can-Fite BioPharma Price Performance
Institutional Trading of Can-Fite BioPharma
An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC grew its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 35.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. 21.00% of the stock is owned by hedge funds and other institutional investors.
Can-Fite BioPharma Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
Featured Articles
- Five stocks we like better than Can-Fite BioPharma
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Which Wall Street Analysts are the Most Accurate?
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.